Purpose To evaluate the safety and visual outcomes of two phakic intraocular lenses (IOLs) for correction of high myopia: Artisan and Visian ICL (ICL). Patients and methods In this retrospective study, a phakic IOL was implanted in 68 highly myopic eyes of 34 patients; 42 eyes received an Artisan IOL, and 26 eyes received ICL IOL.Results All patients completed a 1-year follow-up. The mean preoperative spherical equivalent (SEQ) was À12.89 ± 3.78, and À12.44±4.15 diopters (D) for Artisan and ICL (P ¼ 0.078), respectively. The mean postoperative (1-year) uncorrected distance visual acuity was 0.39±0.13 and 0.41±0.15 logMAR for Artisan and ICL, respectively (P ¼ 0.268). The mean postoperative (1-year) corrected distance visual acuity was 0.36 ± 0.12 and 0.31 ± 0.12 logMAR for Artisan and ICL, respectively (P ¼ 0.128). The mean postoperative SEQ was À0.86±0.5 and À0.63±0.38 D for Artisan and ICL, respectively (P ¼ 0.67). Intraocular pressure change at 1 year was 0.64 ± 2.7 and 1.88 ± 0.6 mm Hg for Artisan and ICL, respectively (P ¼ 0.77). Conclusion Artisan and ICL showed equal and comparable safety, predictability, and efficacy.
Purpose:To evaluate corneal biomechanics with the Ocular Response Analyzer (ORA; Reichert Ophthalmic Instruments, Depew, NY) after penetrating keratoplasty (PK) and deep anterior lamellar keratoplasty (DALK).Subjects and methods:Sixty-three eyes of 63 patients were included in this prospective comparative study. Patients were divided into 3 groups: the first included 21 eyes of normal subjects (control group); the second included 21 eyes with PK; the third included 21 eyes with DALK. ORA was performed 2 months postoperatively for all patients.Results:Both mean corneal hysteresis (CH) and mean corneal resistance factor (CRF) were significantly lower in the PK group than both the DALK group and matched controls. No statistically significant difference was found between mean CH and mean CRF between the DALK group and matched controlsConclusion:Corneas after PK have weaker biomechanical properties than normal corneas. DALK preserves the biomechanical strength of the corneas to almost normal values.
Patient: Male, 27 Final Diagnosis: Cerebral venous sinus thrombosis Symptoms: Headache • seizure • weakness Medication: — Clinical Procedure: — Specialty: Gastroenterology and Hepatology Objective: Rare disease Background: Extra-intestinal manifestations of inflammatory bowel disease (IBD) include thromboembolic events that can present as deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis. Cerebral venous sinus thrombosis is a rare complication of IBD that can be associated with high morbidity and mortality. This report is of a case of cerebral venous sinus thrombosis presenting in a young man during a relapse of ulcerative colitis (UC). Case Report: A 27-year-old man presented with seizures and focal neurological deficit during a relapse of chronic UC. He was found to have left cerebral venous sinus thrombosis complicated by left frontotemporal infarction that was treated with anticoagulation therapy. Conclusions: Thromboembolic events are well documented extra-intestinal manifestation of IBD. Cerebral venous sinus thrombosis is a rare but serious complication that can be fatal. The correct diagnosis and timely management require a high degree of suspicion in patients with IBD who present with a new-onset headache, focal neurological symptoms, seizure, or altered mental status.
Background:The purpose of this study was to evaluate the efficacy and safety of a new instrument to optimize the size, shape, and centration of anterior capsulorhexis.Methods:The study was divided into two parts. The first part was done in 10 goats’ eyes. A specially designed capsulorhexis marker was used. The lower edge of the instrument was stained by gentian violet and then applied to the anterior capsule to produce a circular mark of 5.5 mm. In five eyes, the gentian violet was applied to the marker using a corneal marking pen; in the remaining five eyes, the gentian violet was applied using a corneal marking pad. In the second part, the toxicity of gentian violet was tested as follows: ten albino rabbits received a gentian violet injection into the anterior chamber in one eye (experimental group) and an equal volume of balanced salt solution in the fellow eye (control group). Five rabbits were sacrificed one day after surgery and the remaining five rabbits after one week.Results:In the first part, there was no difficulty in the introduction or removal of the instrument from all eyes. In the first two eyes, the circular mark was diffuse due to sliding of the marker on the surface of the anterior capsule. In the remaining eight eyes, there was a well-centered, rounded mark which was adequately stained. In the second part, there was no histopathological evidence of corneal toxicity in either group. There was loss of ganglion cells from the neurosensory retina one day after surgery in one eye from the experimental group. At one week, there was no evidence of retinal toxicity in any of the rabbits.Conclusion:This capsulorhexis marker can guide the surgeon to a better centration and proper sizing of anterior capsulorhexis using gentian violet staining. More refinement of the instrument is needed to be able to use it in human eyes.
Treatments to correct mixed astigmatism vary in ablation profiles and depth. Bitoric ablation appears to be safer, more effective, and more tissue sparing than the standard treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.